Stock DNA
Pharmaceuticals & Biotechnology
INR 11,261 Cr ()
55.00
34
0.00%
0.00
0.00%
14.60
Total Returns (Price + Dividend) 
Corona Remedies for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns
Corona Remedies Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 May 2026. This shift reflects a combination of deteriorating technical indicators, flat recent financial performance, and valuation concerns despite the company’s strong return on capital employed and institutional investor interest.
Read MoreHas Corona Remedies Ltd declared dividend?
Corona Remedies Ltd has declared a 100% dividend. Dividend Details: - Percentage announced: 100% - Ex-date: 19 Jun 26 Dividend Yield: 0% Total Returns by Period: In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%. Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%. For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%. For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%. Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%. Overa...
Read More
Corona Remedies Ltd Quality Grade Upgrade Reflects Strengthened Business Fundamentals
Corona Remedies Ltd has recently seen its quality grade upgraded from "does not qualify" to "good," reflecting notable improvements in its core business fundamentals. This upgrade, announced on 12 May 2026, highlights enhanced operational efficiency, robust capital returns, and prudent debt management, positioning the small-cap pharmaceutical company favourably within its sector despite recent share price volatility.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Jun-2026 | Source : BSENewspaper Publication - Notice of 22nd Annual General Meeting Intimation of Record Date and E-voting information
Notice Of 22Nd Annual General Meeting
15-Jun-2026 | Source : BSENotice of 22nd Annual General Meeting scheduled to be held on Thursday July 09 2026
Business Responsibility and Sustainability Reporting (BRSR)
15-Jun-2026 | Source : BSEBusiness Responsibility and Sustainability Reporting for the F.Y. 2025-26
Corporate Actions 
No Upcoming Board Meetings
Corona Remedies Ltd has declared 100% dividend, ex-date: 19 Jun 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 17 Schemes (6.35%)
Held by 21 FIIs (2.25%)
Ankurbhai K Mehta (22.0%)
Sepia Investments Limited (19.76%)
0.77%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025
Annual Results Snapshot (Standalone) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period